The humanized anti-SLAMF7 monoclonal antibody elotuzumab [25,26] has been developed and shown promising efficacy in phase 1 and 2 trials on patients with refractory and relapsed multiple myeloma [27]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.